|Dr. Severin Schwan||CEO & Exec. Director||N/A||N/A||1967|
|Dr. Alan Hippe||Chief Financial & IT Officer||N/A||N/A||1967|
|Dr. Karl Mahler||Head of Investor Relations||N/A||N/A||N/A|
|Dr. Urs Jaisli||Chief Compliance Officer||N/A||N/A||1956|
|Ms. Claudia Böckstiegel||Gen. Counsel||N/A||N/A||1964|
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, obesity, ophthalmology, osteoporosis, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, and women's health, as well oncology. In addition, it provides supplies a array of instruments and reagents, and test kits for use in the diverse research market. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Roche Holding AG’s ISS Governance QualityScore as of December 6, 2019 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 1; Compensation: 8.